LATANOPROSTENE BUNOD - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for latanoprostene bunod and what is the scope of freedom to operate?
Latanoprostene bunod
is the generic ingredient in one branded drug marketed by Bausch And Lomb and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Latanoprostene bunod has fifty-three patent family members in thirty-eight countries.
One supplier is listed for this compound.
Summary for LATANOPROSTENE BUNOD
| International Patents: | 53 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 23 |
| Clinical Trials: | 6 |
| Patent Applications: | 114 |
| What excipients (inactive ingredients) are in LATANOPROSTENE BUNOD? | LATANOPROSTENE BUNOD excipients list |
| DailyMed Link: | LATANOPROSTENE BUNOD at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LATANOPROSTENE BUNOD
Generic Entry Date for LATANOPROSTENE BUNOD*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION/DROPS;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LATANOPROSTENE BUNOD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bausch & Lomb Incorporated | Phase 4 |
| Salus University | Phase 4 |
| Icahn School of Medicine at Mount Sinai | Phase 4 |
Paragraph IV (Patent) Challenges for LATANOPROSTENE BUNOD
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VYZULTA | Ophthalmic Solution | latanoprostene bunod | 0.024% | 207795 | 1 | 2022-03-31 |
US Patents and Regulatory Information for LATANOPROSTENE BUNOD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LATANOPROSTENE BUNOD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LATANOPROSTENE BUNOD
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 1906159 | Prostaglandin nitrooxyderivatives | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2005068421 | ⤷ Try a Trial | |
| Morocco | 28284 | Nitro-oxydérivés de prostaglandines | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
